Bioglan Pharma
Article Abstract:
The biotech sector saw erratic share-price performance in 1998 and thee were the usual trial failures. Bioglan Pharma, which was floated last December, uses its revenues to finance the biotech arm of its business. It was established in 1985, rapidly purchasing products, technologies and businesses, and it now has operations in France, Germany, Portugal, Ireland, the US and Scandinavia. Nearly 70% of its sales are in dermatology, and it recent purchased Zeneca's dermatology products. Around a third of its revenues come from licensing deals and milestone payments. Medium term rapid growth will come from introducing the dermatology range to new countries, and it is seeking to expand in the US.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Oxford Molecular
Article Abstract:
Oxford Molecular (OM) aims to achieve the critical mass needed to establish a software system for drug development that becomes an industry standard. The company should benefit from strong demand for such software, and is collaborating with Glaxo Wellcome to develop a system. OM holds marketing rights in this collaboration, and has carried out a number of acquisitions, such as IntelliGenetics. The company is ahead of the competition due to its expansion, though there are also risks involved, and shares in OM are a speculative investment.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic: